Mark A. J. Gorris (Radboud University Medical Center, Nijmegen, The Netherlands) presented a clinical trial (NCT01885702) in which 23 LS patients were vaccinated with dendritic cells loaded with FSPs derived from two genes: transforming growth factor beta receptor 2 (TGFβR2) and caspase 5 (CASP5). The gene discussed is CASP5; the disease is Leigh syndrome.